Evidence map›Paper›PMID 36875315›Full record

ReviewCancer diagnosis & prognosis

Anti-EGFR/BRAF-Tyrosine Kinase Inhibitors in Thyroid Carcinoma.

Vasileios Papanikolaou, Efthymios Kyrodimos, Nicholas Mastronikolis, Asimakis D Asimakopoulos, George Papanastasiou, Evangelos Tsiambas, Despoina Spyropoulou, Spyros Katsinis, Arezina Manoli, Sotirios Papouliakos and 4 more

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer diagnosis & prognosis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Observational
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 3 countries.

Vasileios Papanikolaou1st Department of Otorhinolaryngology, Hippocration Hospital, University of Athens, Athens, Greece.
Efthymios Kyrodimos1st Department of Otorhinolaryngology, Hippocration Hospital, University of Athens, Athens, Greece.
Nicholas MastronikolisDepartment of Otorhinolaryngology, Medical School, University of Patras, Patras, Greece.
Asimakis D AsimakopoulosDepartment of Otorhinolaryngology, Centre Hospital, Sion, Switzerland.
George PapanastasiouDepartment of Maxillofacial, Medical School, University of Ioannina, Ioannina, Greece.
Evangelos TsiambasDepartment of Cytology, 417 Veterans Army Hospital (NIMTS), Athens, Greece.
Despoina SpyropoulouDepartment of Radiation Oncology, Medical School, University of Patras, Patras, Greece.
Spyros KatsinisDepartment of Otorhinolaryngology, Pamakaristos General Hospital, Athens, Greece.
Arezina ManoliDepartment of Otorhinolaryngology, Thoracic Diseases General Hospital Sotiria, Athens, Greece.
Sotirios PapouliakosDepartment of Otorhinolaryngology, General Hospital "Gennimatas", Athens, Greece.
Pavlos Pantos1st Department of Otorhinolaryngology, Hippocration Hospital, University of Athens, Athens, Greece.
Vasileios RagosDepartment of Maxillofacial, Medical School, University of Ioannina, Ioannina, Greece.
Dimitrios PeschosDepartment of Physiology, Medical School, University of Ioannina, Ioannina, Greece.
Aristeidis Chrysovergis1st Department of Otorhinolaryngology, Hippocration Hospital, University of Athens, Athens, Greece.
Hippocration General Hospital · GRUniversity of Ioannina · GRNIMTS Hospital · GRUniversity of Patras · GRAgios Pavlos General Hospital · GRGeneral Hospital of Athens G. Genimatas · GRHôpital de Sion · CHSotiria General Hospital · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alterations in significant genes located on chromosome 7 - including epidermal growth factor receptor (EGFR) and also v-Raf murine sarcoma viral oncogene homolog B (BRAF) as a mitogen-activated protein kinase (MAPK)  - combined or not with numerical imbalances of the whole chromosome (aneuploidy-polysomy) are crucial genetic events involved in the development and progression of malignancies. Identification of EGFR/BRAF-dependent specific somatic mutations and other mechanisms of deregulation (i.e., amplification) is critical for applying targeted therapeutic approaches [tyrosine kinase inhibitors (TKIs] or monoclonal antibodies (mAbs). Thyroid carcinoma is a specific pathological entity characterized by a variety of histological sub-types. Follicular thyroid carcinoma (FTC), papillary thyroid carcinoma (PTC), medullary thyroid carcinoma (MTC), and anaplastic thyroid carcinoma (ATC) represent its main sub-types. In the current review, we explore the role of EGFR/BRAF alterations in thyroid carcinoma in conjunction with the corresponding anti-EGFR/BRAF TKI-based novel therapeutic strategies for patients with specific genetic signatures.

Indexed as

carcinomaepidermal growth factorkinasereceptorreviewThyroidtyrosine

Identifiers

PMID36875315
PMCPMC9949544
OpenAlexW4323294099

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.